688131 皓元医药
已收盘 11-16 15:00:00
资讯
新帖
简况
股市必读:皓元医药(688131)11月16日披露最新机构调研信息
证券之星 · 48分钟前
股市必读:皓元医药(688131)11月16日披露最新机构调研信息
皓元医药:截至2026年9月30日,公司股东总户数为14,189户
证券之星 · 11-09
皓元医药:截至2026年9月30日,公司股东总户数为14,189户
【机构调研记录】民生加银基金调研皓元医药、帝欧水华
证券之星 · 11-06
【机构调研记录】民生加银基金调研皓元医药、帝欧水华
股市必读:皓元医药(688131)11月5日披露最新机构调研信息
证券之星 · 11-06
股市必读:皓元医药(688131)11月5日披露最新机构调研信息
轩竹生物-B盘中涨超15%,与皓元医药达成全面战略合作
同花顺 · 11-03
轩竹生物-B盘中涨超15%,与皓元医药达成全面战略合作
皓元医药与轩竹生物达成全面战略合作
格隆汇 · 11-03
皓元医药与轩竹生物达成全面战略合作
皓元医药(688131)披露关于不提前赎回“皓元转债”的公告,11月02日股价上涨1.75%
证券之星 · 11-02
皓元医药(688131)披露关于不提前赎回“皓元转债”的公告,11月02日股价上涨1.75%
皓元医药(688131)9月30日股东户数1.42万户,较上期减少10.66%
证券之星 · 10-30
皓元医药(688131)9月30日股东户数1.42万户,较上期减少10.66%
10月30日皓元医药涨10.79%,科创创新药ETF国泰基金重仓该股
证券之星 · 10-30
10月30日皓元医药涨10.79%,科创创新药ETF国泰基金重仓该股
皓元医药涨10.79%,开源证券二个月前给出“买入”评级
证券之星 · 10-30
皓元医药涨10.79%,开源证券二个月前给出“买入”评级
皓元医药前三季度营收26.5亿元 同比增长28.5%
同花顺 · 10-30
皓元医药前三季度营收26.5亿元 同比增长28.5%
皓元医药涨7.15%,开源证券二个月前给出“买入”评级
证券之星 · 10-28
皓元医药涨7.15%,开源证券二个月前给出“买入”评级
皓元医药(688131)10月27日主力资金净买入1727.35万元
证券之星 · 10-28
皓元医药(688131)10月27日主力资金净买入1727.35万元
皓元医药最新公告:全资子公司通过美国FDA现场检查
证券之星 · 10-27
皓元医药最新公告:全资子公司通过美国FDA现场检查
10月27日皓元医药跌6.00%,科创创新药ETF国泰基金重仓该股
证券之星 · 10-27
10月27日皓元医药跌6.00%,科创创新药ETF国泰基金重仓该股
股市必读:皓元医药新发布《上海皓元医药股份有限公司关于“皓元转债”预计满足赎回条件的提示性公告》
证券之星 · 10-26
股市必读:皓元医药新发布《上海皓元医药股份有限公司关于“皓元转债”预计满足赎回条件的提示性公告》
皓元医药(688131)披露“皓元转债”预计满足赎回条件的提示性公告,10月23日股价上涨2.4%
证券之星 · 10-23
皓元医药(688131)披露“皓元转债”预计满足赎回条件的提示性公告,10月23日股价上涨2.4%
皓元医药(688131)10月19日主力资金净买入846.30万元
证券之星 · 10-20
皓元医药(688131)10月19日主力资金净买入846.30万元
皓元医药(688131)10月16日主力资金净卖出643.72万元
证券之星 · 10-17
皓元医药(688131)10月16日主力资金净卖出643.72万元
10月16日皓元医药跌5.48%,科创创新药ETF国泰基金重仓该股
证券之星 · 10-16
10月16日皓元医药跌5.48%,科创创新药ETF国泰基金重仓该股
加载更多
公司概况
公司名称:
上海皓元医药股份有限公司
所属行业:
研究和试验发展
上市日期:
2021-06-08
主营业务:
上海皓元医药股份有限公司的主营业务是药物发现领域的生命科学试剂的研发,原料药、中间体、起始物料及制剂的药物研发,工艺优化及商业化生产。公司的主要产品是生命科学试剂业务、原料药和中间体、制剂业务。
发行价格:
64.99
{"stockData":{"symbol":"688131","market":"SH","secType":"STK","nameCN":"皓元医药","latestPrice":92,"timestamp":1794812400000,"preClose":93,"halted":0,"volume":3161578,"delay":0,"changeRate":-0.0108,"floatShares":213000000,"shares":213000000,"eps":1.4631,"marketStatus":"已收盘","change":-1,"latestTime":"11-16 15:00:00","open":92.22,"high":94.69,"low":90.4,"amount":292000000,"amplitude":0.0461,"askPrice":92.01,"askSize":4,"bidPrice":92,"bidSize":13,"shortable":0,"etf":0,"ttmEps":1.4631,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794879000000},"marketStatusCode":5,"adr":0,"adjPreClose":93,"symbolType":"stock_kcb","openAndCloseTimeList":[[1794792600000,1794799800000],[1794805200000,1794812400000]],"highLimit":102.3,"lowLimit":83.7,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":213234116,"isCdr":false,"pbRate":5.87,"roa":"--","peRate":62.880186,"roe":"9.37%","epsLYR":1.13,"committee":0.194805,"marketValue":19618000000,"turnoverRate":0.0148,"status":1,"afterMarket":{"amount":0,"volume":0,"close":92,"buyVolume":0,"sellVolume":200,"time":1794814437746,"indexStatus":"已收盘 11-16 15:30:00","preClose":93},"floatMarketCap":19618000000},"requestUrl":"/m/hq/s/688131","defaultTab":"news","newsList":[{"id":"2684446566","title":"股市必读:皓元医药(688131)11月16日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2684446566","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684446566?lang=zh_cn&edition=full","pubTime":"2026-11-17 02:24","pubTimestamp":1794853452,"startTime":"0","endTime":"0","summary":"截至2026年11月16日收盘,皓元医药报收于92.0元,下跌1.08%,换手率1.48%,成交量3.16万手,成交额2.92亿元。机构调研要点:2026年前三季度前端生命科学试剂业务收入18.95亿元,同比增长30.83%,占主营业务收入比重达72%。皓元转债在2027年1月31日前不触发强制赎回;自2027年2月1日起重新计算赎回条款,若再次触发,董事会将另行审议是否行使提前赎回权。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111700001434.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688131"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682805915","title":"皓元医药:截至2026年9月30日,公司股东总户数为14,189户","url":"https://stock-news.laohu8.com/highlight/detail?id=2682805915","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682805915?lang=zh_cn&edition=full","pubTime":"2026-11-09 17:21","pubTimestamp":1794216103,"startTime":"0","endTime":"0","summary":"证券之星消息,皓元医药(688131)11月09日在投资者关系平台上答复投资者关心的问题。投资者提问:请问公司最新一期的股东户数是多少?谢谢皓元医药回复:尊敬的投资者您好,根据信息披露公平原则,公司会在定期报告中按照中国证监会、上交所相关要求对对应期末时点的股东户数进行披露。截至2026年9月30日,公司股东总户数为14,189户,具体内容详见《上海皓元医药股份有限公司2026年第三季度报告》。感谢您的理解与支持,谢谢!本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110900016347.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688131","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681881581","title":"【机构调研记录】民生加银基金调研皓元医药、帝欧水华","url":"https://stock-news.laohu8.com/highlight/detail?id=2681881581","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681881581?lang=zh_cn&edition=full","pubTime":"2026-11-06 08:02","pubTimestamp":1793923345,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及11月5日披露的机构调研信息,民生加银基金近期对2家上市公司进行了调研,相关名单如下:1)皓元医药 调研纪要:2026年前三季度,公司实现营业收入26.5亿元,同比增长28.5%;归母净利润3.1亿元,同比增长30.5%。民生加银基金成立于2008年,截至目前,资产管理规模1486.16亿元;资产管理规模1190.97亿元;管理公募基金数192只;旗下公募基金经理31人。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110600008115.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002798","BK0216","688131","BK0235"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681003008","title":"股市必读:皓元医药(688131)11月5日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2681003008","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681003008?lang=zh_cn&edition=full","pubTime":"2026-11-06 01:06","pubTimestamp":1793898379,"startTime":"0","endTime":"0","summary":"截至2026年11月5日收盘,皓元医药报收于101.0元,上涨0.2%,换手率3.08%,成交量6.56万手,成交额6.66亿元。当日关注点交易信息汇总:11月5日主力资金净流入1684.23万元,占总成交额2.53%。其中,第三季度实现营收10.0亿元,同比增长33.4%;归母净利润1.3亿元,同比增长62.1%。2026年前三季度计提存货跌价准备1.35亿元。截至2026年三季度末,公司在手订单金额为10.9亿元,较2024年末翻倍。药源启东基地和马鞍山科创园基地于2026年以零缺陷通过美国FDA现场检查。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110600001643.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688131","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680471565","title":"轩竹生物-B盘中涨超15%,与皓元医药达成全面战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2680471565","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680471565?lang=zh_cn&edition=full","pubTime":"2026-11-03 11:25","pubTimestamp":1793676300,"startTime":"0","endTime":"0","summary":"11月3日,轩竹生物-B(02575.HK)盘中涨超15%,截至11时22分,涨15.78%,报8.950港元/股,成交额2816.29万港元。消息面上。据皓元医药消息,皓元医药与轩竹生物正式签署全面战略合作协议。双 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20261103/c681394044.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20261103/c681394044.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0216","688131"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680680792","title":"皓元医药与轩竹生物达成全面战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2680680792","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680680792?lang=zh_cn&edition=full","pubTime":"2026-11-03 08:30","pubTimestamp":1793665839,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["688131","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680756410","title":"皓元医药(688131)披露关于不提前赎回“皓元转债”的公告,11月02日股价上涨1.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680756410","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680756410?lang=zh_cn&edition=full","pubTime":"2026-11-02 19:23","pubTimestamp":1793618591,"startTime":"0","endTime":"0","summary":"截至2026年11月2日收盘,皓元医药报收于93.7元,较前一交易日上涨1.75%,最新总市值为199.8亿元。该股当日开盘91.0元,最高95.54元,最低90.44元,成交额达6.31亿元,换手率为3.19%。公告显示,公司股票在2026年10月12日至10月30日期间,连续三十个交易日内有十五个交易日收盘价不低于“皓元转债”当期转股价格40.13元/股的130%,已触发有条件赎回条款。公司于2026年10月30日召开董事会,决定本次不行使“皓元转债”的提前赎回权利。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110200029199.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688131","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679213839","title":"皓元医药(688131)9月30日股东户数1.42万户,较上期减少10.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679213839","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679213839?lang=zh_cn&edition=full","pubTime":"2026-10-30 19:11","pubTimestamp":1793358663,"startTime":"0","endTime":"0","summary":"证券之星消息,近日皓元医药披露,截至2026年9月30日公司股东户数为1.42万户,较6月30日减少1693.0户,减幅为10.66%。在医疗服务行业个股中,皓元医药股东户数低于行业平均水平,截至9月30日,医疗服务行业平均股东户数为4.99万户。从股价来看,2026年6月30日至2026年9月30日,皓元医药区间涨幅为5.42%,在此期间股东户数减少1693.0户,减幅为10.66%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000046477.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688131"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679293028","title":"10月30日皓元医药涨10.79%,科创创新药ETF国泰基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2679293028","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679293028?lang=zh_cn&edition=full","pubTime":"2026-10-30 16:54","pubTimestamp":1793350477,"startTime":"0","endTime":"0","summary":"证券之星消息,10月30日皓元医药涨10.79%,收盘报92.09元,换手率5.07%,成交量10.81万手,成交额9.73亿元。根据2026基金Q3季报公募基金重仓股数据,重仓该股的公募基金共54家,其中持有数量最多的公募基金为国泰基金的科创创新药ETF国泰。科创创新药ETF国泰目前规模为41.96亿元,最新净值0.7546,较上一交易日下跌1.78%,近一年下跌19.16%。科创创新药ETF国泰的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000041391.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["589720","688131","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679958752","title":"皓元医药涨10.79%,开源证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2679958752","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679958752?lang=zh_cn&edition=full","pubTime":"2026-10-30 16:54","pubTimestamp":1793350463,"startTime":"0","endTime":"0","summary":"今日皓元医药涨10.79%,收盘报92.09元。2026年8月28日,开源证券研究员余汝意发布了对皓元医药的研报《公司信息更新报告:前端业务高景气驱动收入增长,后端订单加速蓄能》,该研报对皓元医药给出“买入”评级。研报中预计2026-2028年公司归母净利润为3.51/5.26/7.20亿元,EPS为1.65/2.47/3.38元,当前股价对应PE为56.9/37.9/27.7倍,维持“买入”评级。皓元医药个股概况:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000041381.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","688131"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679326210","title":"皓元医药前三季度营收26.5亿元 同比增长28.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679326210","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679326210?lang=zh_cn&edition=full","pubTime":"2026-10-30 15:32","pubTimestamp":1793345520,"startTime":"0","endTime":"0","summary":" 本报讯(记者金婉霞)10月29日晚间,上海皓元医药股份有限公司(以下简称“皓元医药”)披露2026年三季度报告。前三季度,该公司实现营业收入26.5亿元,同比增长28.5% ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261030/c681288394.shtml","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261030/c681288394.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["688131"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678451998","title":"皓元医药涨7.15%,开源证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2678451998","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678451998?lang=zh_cn&edition=full","pubTime":"2026-10-28 16:40","pubTimestamp":1793176833,"startTime":"0","endTime":"0","summary":"今日皓元医药涨7.15%,收盘报83.37元。2026年8月28日,开源证券研究员余汝意发布了对皓元医药的研报《公司信息更新报告:前端业务高景气驱动收入增长,后端订单加速蓄能》,该研报对皓元医药给出“买入”评级。研报中预计2026-2028年公司归母净利润为3.51/5.26/7.20亿元,EPS为1.65/2.47/3.38元,当前股价对应PE为56.9/37.9/27.7倍,维持“买入”评级。皓元医药个股概况:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102800036531.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","688131"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678253480","title":"皓元医药(688131)10月27日主力资金净买入1727.35万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2678253480","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678253480?lang=zh_cn&edition=full","pubTime":"2026-10-28 08:46","pubTimestamp":1793148383,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年10月27日收盘,皓元医药报收于77.81元,下跌6.0%,换手率2.44%,成交量5.19万手,成交额4.17亿元。10月27日的资金流向数据方面,主力资金净流入1727.35万元,占总成交额4.15%,游资资金净流入2547.65万元,占总成交额6.12%,散户资金净流出4275.01万元,占总成交额10.26%。近5日资金流向一览见下表:皓元医药融资融券信息显示,融资方面,当日融资买入4641.15万元,融资偿还2760.88万元,融资净买入1880.28万元,连续3日净买入累计3702.22万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102800014247.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688131","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678500179","title":"皓元医药最新公告:全资子公司通过美国FDA现场检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2678500179","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678500179?lang=zh_cn&edition=full","pubTime":"2026-10-27 19:11","pubTimestamp":1793099502,"startTime":"0","endTime":"0","summary":"皓元医药(688131.SH)公告称,公司全资子公司安徽皓元药业于2026年8月17日至21日接受美国FDA现场监督检查,近日收到检查报告,确认以NAI零缺陷通过。此次通过标志着其质量体系符合美国FDA要求,有助于拓展国际市场,对公司经营业绩和竞争力产生积极影响。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102700036695.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688131","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678112103","title":"10月27日皓元医药跌6.00%,科创创新药ETF国泰基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2678112103","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678112103?lang=zh_cn&edition=full","pubTime":"2026-10-27 16:48","pubTimestamp":1793090924,"startTime":"0","endTime":"0","summary":"证券之星消息,10月27日皓元医药跌6.00%,收盘报77.81元,换手率2.44%,成交量5.19万手,成交额4.17亿元。根据2026基金Q3季报公募基金重仓股数据,重仓该股的公募基金共40家,其中持有数量最多的公募基金为国泰基金的科创创新药ETF国泰。科创创新药ETF国泰目前规模为41.96亿元,最新净值0.7991,较上一交易日下跌1.75%,近一年下跌14.01%。科创创新药ETF国泰的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102700031481.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","589720","688131"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678136158","title":"股市必读:皓元医药新发布《上海皓元医药股份有限公司关于“皓元转债”预计满足赎回条件的提示性公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2678136158","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678136158?lang=zh_cn&edition=full","pubTime":"2026-10-26 02:44","pubTimestamp":1792953851,"startTime":"0","endTime":"0","summary":"公司公告汇总上海皓元医药股份有限公司关于“皓元转债”预计满足赎回条件的提示性公告上海皓元医药股份有限公司公告,“皓元转债”自2026年10月12日至10月23日已有10个交易日收盘价不低于当期转股价格40.13元/股的130%。若未来连续20个交易日内再有5个交易日收盘价达到该标准,将触发有条件赎回条款。公司有权按债券面值加当期应计利息的价格赎回未转股的可转债。公司将按规定履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102600000745.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688131","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677973641","title":"皓元医药(688131)披露“皓元转债”预计满足赎回条件的提示性公告,10月23日股价上涨2.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2677973641","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677973641?lang=zh_cn&edition=full","pubTime":"2026-10-23 22:38","pubTimestamp":1792766310,"startTime":"0","endTime":"0","summary":"截至2026年10月23日收盘,皓元医药报收于83.99元,较前一交易日上涨2.4%,最新总市值为179.1亿元。该股当日开盘81.1元,最高84.63元,最低78.86元,成交额达3.39亿元,换手率为1.95%。近日,上海皓元医药股份有限公司发布《关于“皓元转债”预计满足赎回条件的提示性公告》。公告显示,“皓元转债”自2026年10月12日至10月23日已有10个交易日收盘价不低于当期转股价格的130%。公司将按规定履行信息披露义务,提醒投资者关注赎回风险。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300045829.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688131"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676320686","title":"皓元医药(688131)10月19日主力资金净买入846.30万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2676320686","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676320686?lang=zh_cn&edition=full","pubTime":"2026-10-20 08:22","pubTimestamp":1792455739,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年10月19日收盘,皓元医药报收于83.55元,上涨2.6%,换手率2.68%,成交量5.72万手,成交额4.68亿元。10月19日的资金流向数据方面,主力资金净流入846.3万元,占总成交额1.81%,游资资金净流入2327.94万元,占总成交额4.97%,散户资金净流出3174.24万元,占总成交额6.78%。近5日资金流向一览见下表:皓元医药融资融券信息显示,融资方面,当日融资买入3668.53万元,融资偿还3442.37万元,融资净买入226.16万元,连续3日净买入累计3032.86万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102000005129.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688131"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676510691","title":"皓元医药(688131)10月16日主力资金净卖出643.72万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2676510691","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676510691?lang=zh_cn&edition=full","pubTime":"2026-10-17 08:21","pubTimestamp":1792196487,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年10月16日收盘,皓元医药报收于81.43元,下跌5.48%,换手率2.81%,成交量5.99万手,成交额5.07亿元。10月16日的资金流向数据方面,主力资金净流出643.72万元,占总成交额1.27%,游资资金净流入4063.57万元,占总成交额8.02%,散户资金净流出3419.86万元,占总成交额6.75%。融券方面,融券卖出1200.0股,融券偿还1140.0股,融券余量6.55万股,融券余额533.55万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101700005761.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688131","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675562252","title":"10月16日皓元医药跌5.48%,科创创新药ETF国泰基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2675562252","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675562252?lang=zh_cn&edition=full","pubTime":"2026-10-16 16:31","pubTimestamp":1792139480,"startTime":"0","endTime":"0","summary":"证券之星消息,10月16日皓元医药跌5.48%,收盘报81.43元,换手率2.81%,成交量5.99万手,成交额5.07亿元。根据2026基金半年报公募基金重仓股数据,重仓该股的公募基金共28家,其中持有数量最多的公募基金为国泰基金的科创创新药ETF国泰。科创创新药ETF国泰目前规模为21.97亿元,最新净值0.7888,较上一交易日下跌0.6%,近一年下跌16.32%。科创创新药ETF国泰的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101600027874.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688131","589720"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1794856282784,"stockEarnings":[{"period":"1week","weight":-0.0504},{"period":"1month","weight":0.1298},{"period":"3month","weight":-0.0828},{"period":"6month","weight":0.2235},{"period":"1year","weight":0.1948},{"period":"ytd","weight":0.2797}],"compareEarnings":[{"period":"1week","weight":-0.0159},{"period":"1month","weight":-0.0306},{"period":"3month","weight":-0.0972},{"period":"6month","weight":-0.1345},{"period":"1year","weight":-0.0972},{"period":"ytd","weight":-0.0923}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海皓元医药股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"14189人(较上一季度减少10.66%)","perCapita":"15028股","listingDate":"2021-06-08","address":"上海市浦东新区中国(上海)自由贸易试验区蔡伦路720弄2号501室","registeredCapital":"21323万元","survey":" 上海皓元医药股份有限公司的主营业务是药物发现领域的生命科学试剂的研发,原料药、中间体、起始物料及制剂的药物研发,工艺优化及商业化生产。公司的主要产品是生命科学试剂业务、原料药和中间体、制剂业务。","listedPrice":64.99},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.54.0","shortVersion":"4.54.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"皓元医药(688131)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供皓元医药(688131)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"皓元医药,688131,皓元医药股票,皓元医药股票老虎,皓元医药股票老虎国际,皓元医药行情,皓元医药股票行情,皓元医药股价,皓元医药股市,皓元医药股票价格,皓元医药股票交易,皓元医药股票购买,皓元医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"皓元医药(688131)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供皓元医药(688131)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}